Dunn, B., Stein, P., & Cavazzoni, P. (2021). Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective. JAMA internal medicine, 181(10), 1276. https://doi.org/10.1001/jamainternmed.2021.4607
Citácia podle Chicago (17th ed.)Dunn, Billy, Peter Stein, a Patrizia Cavazzoni. "Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective." JAMA Internal Medicine 181, no. 10 (2021): 1276. https://doi.org/10.1001/jamainternmed.2021.4607.
Citácia podľa MLA (8th ed.)Dunn, Billy, et al. "Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective." JAMA Internal Medicine, vol. 181, no. 10, 2021, p. 1276, https://doi.org/10.1001/jamainternmed.2021.4607.
Upozornenie: Tieto citáce sú generované automaticky. Nemusia byť úplne správne podľa citačných pravidiel..